Targacept is advancing TC-5214 into clinical development as an augmentation therapy for patients who experience an inadequate response to antidepressants. The company expects to initiate a Phase I trial of TC-5214 in the first quarter of 2008 with Phase II development to start soon after. The company has no current plans to conduct further clinical development of mecamylamine.
"Major depression is a serious medical illness affecting 15 million American adults, and the current treatment options simply are not adequate for many people," said Ranga Krishnan, M.D., chair of the Department of Psychiatry at the Duke University Medical Center. "The results from Targacept's Phase II efficacy trial of mecamylamine as an augmentation therapy to citalopram helped establish the NNR mechanism as a potential new treatment paradigm for depression."
- check out the release
GSK inks $1.5B dollar pain deal with Targacept. Report
Targacept raises IPO cash. Report
Targacept takes second shot at $60M IPO. Report
Targacept gains $20M payment from AstraZeneca. Report